Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Recommendation of “Hold” from Analysts
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned an average rating of “Hold” from the twelve analysts that are covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned an average rating of “Hold” from the twelve analysts that are covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers […]
